Orum Therapeutics is a public biotechnology company pioneering the development of Degrader-Antibody Conjugates (DACs). Our mission is to cure cancer and other serious diseases by combining the precise tumor-targeting power of antibodies with the potent intracellular destruction capability of targeted protein degraders(TPD).

Orum Therapeutics, Inc. is incorporated in South Korea.

We operate as a global biotech to leverage the best talent and infrastructure in both regions:

• HQ and Lab: Daejeon, South Korea

• US Lab : Lexington, Massachusetts, USA

Unlike traditional Targeted Protein Degraders (TPDs) that can affect healthy cells, or traditional Antibody-Drug Conjugates (ADCs) that typically use cytotoxic payloads, Orum’s DAC approach uses antibodies to selectively deliver novel protein degrader payloads directly into target cells. This targeted delivery is designed to improve the therapeutic window, potentially enhancing safety and efficacy. Our GSPT1 platform uses molecular glue degraders targeting GSPT1 as payloads.

While both use antibodies to target cancer cells, the difference lies in the payload (the "warhead"):

• Traditional ADC: Uses a chemotherapy toxin to kill the cell.

• DAC: Uses a protein degrader (molecular glue) to degrade specific proteins essential for cancer cell survival (such as GSPT1). This allows us to kill cancer cells that might be resistant to chemotherapy or traditional ADCs.

We have validated our platform through high-profile global partnerships:

* Bristol Myers Squibb: Acquired the ORM-6151 program.

* Vertex Pharmaceuticals: Entered a multi-target license and option agreement to use Orum’s proprietary DAC technology for gene editing conditioning agents.

Our lead internal asset is ORM-1153, a DAC that targets CD123 to deliver a GSPT1 degrader. It is being developed for the treatment of hematologic malignancies. We are also advancing a broader preclinical pipeline using our PROTAb platform.

This information is available our About page.

Orum Therapeutics is listed on the KOSDAQ market in South Korea.

• Ticker Symbol: 475830

• Bloomberg Ticker: 475830:KS

Orum is listed on the KOSDAQ market. Shares may be purchased through a registered broker-dealer or an online trading platform of your choice. Major international brokerages and banks often offer access to trade Korean stock. Shares cannot be purchased directly from the company.

• Korean Filings: You can view our official disclosures on the DART (Data Analysis, Retrieval and Transfer System) website run by the Korean Financial Supervisory Service (FSS). These are also available on our ‘Filings’ page under IR

• US Filings: As a KOSDAQ-listed entity, our primary reporting is in South Korea, but major material news is released globally in English via our Investor Relations page and email subscription.
  

Our fiscal year ends on December 31st.

Orum does not distribute dividends on its common stock.

Orum Therapeutics does not currently pay cash dividends. As pre-commercial biotechnology company, we prioritize reinvesting our capital into research and development (R&D) to advance our pipeline and maximizing long-term shareholder value.

For shares held in Korea, the Korea Securities Depository (KSD) acts as the transfer agent. International investors typically hold shares through a global custodian or broker with access to the Korean exchange.

For institutional inquiries, partnership opportunities, or shareholder questions, please refer to our contact page.

You can sign up for email updates through our distribution list here.

The sale by Director, Peter Park was conducted specifically to secure the necessary funds for the payment of withholding taxes incurred by the exercise of stock options this year. At this time, we understand that the Director has no immedate plans for additional share sales.

Management is very aware of the current share price situation and views it with strong importance. This exercise pertains to stock options granted since 2021 and was conducted as part of fulfilling pre-established contractual obligations designed to secure and compensate key global talent.
Our entire team remains dedicated to prioritizing shareholder value above all else. We are committed to driving a recovery in the share price by generating strong operational results, and we will do our best to not only meet but exceed the expectations of our shareholders.

We believe the recent drop in stock price mainly reflects market concerns regarding the biotech sector driven by global external environment variables (rate hike concerns etc); it is not a decline related to the company’s intrinsic value or business.
Our ongoing projects are progressing according to the planned schedule, and we would like to share the current status of each pipeline below.

Pipeline status

ORM-1153

• Robust efficacy and safety data disclosed at the AACR (American Association for Cancer Research)

• Demonstrated powerful in-vitro activity across diverse AML genetic profiles, and confirmed superior and uniform tumor suppression effects and survival benefits compared to standard-of-care regimens and competitor drugs through in vivo mouse models

• Non-human primate(NHP) tox data showed maintenance of key toxicity indicators mainly within the normal range and transient, reversible recovery

• Development is progressing smoothly toward our goal of IND (investigational new drug) submission within this year

ORM-1023

• Research is progressing smoothly according to the currently planned development schedule. We aim to achieve development candidate (DC) nomination in the second half of this year.

New TPD² payloads

• We are currently researching multiple new programs, focusing primarily on solid tumors and immune diseases, and are continuously accumulating and validating data. We plan to sequentially share relevant research achievements as these programs progress in the future

Orum Therapeutics has retained Locust Walk as a strategic advisor to further the company's business development initiatives. Given the potential conflict of interest, Geoffrey Meyerson, CEO of Locust Walk, has voluntarily resigned from his position as an independent director. We intend to propose his appointment as a Non-Executive Director at the next shareholders' meeting. Our relationship with Geoffrey Meyerson remains strong, and we look forward to close cooperation with him and broader Locust Walk team to drive Orum’s next phase of growth.

Following a review of the study data, Bristol Myers Squibb (BMS) decided to discontinue development of BMS-986497(ORM-6151), which it acquired from Orum Therapeutics in 2023.

Orum continues its DAC research and development, including ongoing work on ORM-1153. The company is also developing new payloads for future DAC programs.

ORM-1153, Orum’s lead clinical development program, uses a best-in-class CD123 antibody to deliver Orum’s proprietary GSPT1 payload. It has demonstrated a broad therapeutic index in preclinical studies, and the FDA recently cleared its IND application. Orum is preparing to initiate a Phase 1 study in patients with relapsed or refractory acute myeloid leukemia and other hematologic malignancies.

Dear Shareholders,

We know the past few weeks have been difficult for many of you. On September 17, we disclosed that Bristol Myers Squibb (BMS) decided to stop developing ORM-6151, the leukemia drug candidate it acquired from Orum in 2023, after reviewing Phase 1 clinical data. Our share price has fallen sharply since then. We want to explain plainly what this means for Orum and what we are doing next.

What the BMS Decision Means

Orum will no longer receive up to USD 80 million in future milestone payments tied to ORM-6151. The decision does not affect the USD 100 million upfront payment we received in 2023, which we keep in full and do not have to repay. As of June, Orum held KRW 254.5 bn in cash and short-term investments, which we expect to fund our planned operations through the next few years. ORM-6151 was the first program from our technology to be tested in AML patients, and we share your disappointment. However, our core technology, our team, and our strategy remain in place.

Our Lead Program: ORM-1153

We successfully implemented key design changes derived from clinical learnings, aiming to improve payload delivery efficiency and mitigate safety risks. Specifically, our lead development stage program, ORM-1153, is a CD123-GSPT1 DAC optimized for efficient payload delivery and a wider therapeutic window—attributes that are supported by its robust preclinical data package presented at AACR 2026. ORM-1153 has the potential to be broadly active in AML patients, including the difficult-to-treat TP53 mutant population. With the program’s IND now active, our focus is to begin patient dosing, continue activating clinical sites, and enroll patients efficiently to generate meaningful clinical data in 2027.

Beyond our GSPT1 Platform

We are progressing new DAC payload platforms intended to have broad potential in solid tumors. These new platforms have multi-program potential, which in turn provides opportunities for both partnering and additional product development within Orum. We also have initiated work to expand the utility of our DAC platforms and know-how in the field of autoimmune disease. Our new DAC payload platform and work on DACs for autoimmune are the core focus of our research organization as we finish 2026 and look toward 2027.

Regarding partnering, we are currently focused on the following three areas:

•          First, we have several prospective partners with confirmed interest in ORM-1153, pending the availability of meaningful clinical data in 2027. We will continue to keep these parties updated as we progress through the study.

•          Second, Orum is currently speaking to multiple prospective partners regarding our new, solid-tumor-focused DAC payload platform, as well as our work on DACs for autoimmune disease. Transaction trends for novel payloads in oncology, as well as novel programs and technologies in immunology, suggest prospective partners are open to early-stage, preclinical stage projects, so we are committed to exploring these opportunities.

•          Lastly, we are actively evaluating programs and technologies, such as novel antibodies and degrader payloads, that would be strategically aligned with our internally developed DAC with the aim of speeding our timeline from discovery through clinical development.

Based on the current BD focus and strategy outlined above, we are targeting one or more partnering transactions in 2027.

Our R&D teams remain undeterred by recent market events and are working diligently to advance our robust pipeline. We remain uniquely positioned as a leader in the DAC space, backed by strong capabilities in DAC discovery and deep experience in bringing early pipeline assets into the clinic.

Thank you for your continued trust, patience, and steadfast support as we continue on this path to bring novel treatment options to patients with difficult-to-treat diseases.

on behalf of the Orum Therapeutics team,

Sung Joo Lee, CEO

Orum Therapeutics Forward-Looking Statements

This letter contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the potential therapeutic value of ORM-1153 and Orum’s TPD approach; improvements in payload delivery efficiency and the mitigation of safety risks; the expected initiation, timing, design, enrollment, conduct, and results of clinical trials of ORM-1153; the successful translation of preclinical findings into clinical results; the potential indications for ORM-1153; the potential for ORM-1153 to address unmet medical needs in AML or other hematologic malignancies; the advancement of Orum’s GSPT1-directed TPD programs; the development of additional DAC platforms and their potential to lead to multiple programs; the successful expansion into autoimmune therapies; the potential for additional licensing or sale transactions with partners and the timeline for those transactions; the potential for partners to be open to early stage preclinical projects; and the development of novel antibodies and degrader payloads and their potential benefits, are forward-looking statements.

These forward-looking statements are based on management’s expectations and assumptions as of the date of this letter and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; risks related to clinical trials, including potential delays, safety issues, enrollment challenges, or negative results; competition from alternative therapies; risks related to regulatory review and approval; risks related to third-party manufacturing and development activities; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this letter speak only as of the date of this letter, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this letter.